|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.09 USD | -1.77% |
|
+5.55% | -10.83% |
| May. 16 | AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft | MT |
| May. 02 | Transcript : AxoGen, Inc., Q1 2024 Earnings Call, May 02, 2024 |
AxoGen, Inc. Provided revenue guidance for the year 2023. For the full year, the company provides revenue in the range of $154 million to $159 million which represents annual growth of 11% - 15%.
| 1st Jan change | Capi. | |
|---|---|---|
| -10.83% | 266M | |
| +11.18% | 225B | |
| +15.22% | 197B | |
| +19.19% | 143B | |
| +30.89% | 111B | |
| +1.56% | 64.72B | |
| +18.48% | 54.44B | |
| +5.12% | 51.06B | |
| +10.53% | 45.03B | |
| +5.98% | 37.4B |
AXOGEN, INC. 